Consolidation in Generics Sector As Impax Merges With Amneal
The deal will create the fifth-largest generics company in the US with one of the largest pipelines, with about 150 pending ANDAs and 165 projects in active stages of development.
You may also be interested in...
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.